US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Evommune

28.31

-0.4200-1.46%

Post-market: 28.320.0100+0.04%19:58 EST

Volume:389.57K

Turnover:11.01M

Market Cap:892.45M

PE:-14.20

High:29.64

Open:28.60

Low:26.50

Close:28.73

52wk High:33.20

52wk Low:13.89

Shares:31.52M

Float Shares:9.40M

Volume Ratio:0.57

T/O Rate:4.14%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.9930

EPS(LYR):-45.2873

ROE:--

ROA:--

PB:-4.87

PE(LYR):-0.63

Loading ...

Overview Company News Filings

Evommune price target raised to $54 from $36 at Morgan Stanley

BRIEF-Evommune Inc On Feb 12, Enters Securities Purchase Agreement With Investors

Evommune Inc - to Issue and Sell 4,494,279 Shares of Common Stock - SEC Filing

THOMSON REUTERS

Evommune Inc - Estimates Gross Proceeds of $125 Mln - SEC Filing

THOMSON REUTERS

Evommune Inc - on Feb 12, Enters Securities Purchase Agreement With Investors - SEC Filing

THOMSON REUTERS

Evommune announces $125M private placement

Evommune Raises $125 Million in Private Placement of Common Stock

Evommune Announces $125 Million Private Placement

THOMSON REUTERS

Evommune (EVMN) Valuation Check After Positive Phase 2a EVO301 Results In Atopic Dermatitis

Simply Wall St.

U.S. RESEARCH ROUNDUP-Coca-Cola, Rapid7, Walmart

Top Midday Gainers

MT Newswires Live

Evommune price target raised to $55 from $40 at Evercore ISI

Evommune: Robust IL-18 Phase 2a Atopic Dermatitis Data Underpins Buy Rating and Higher $55 Target with Additional Indication Upside

Evommune Is Maintained at Buy by HC Wainwright & Co.

Evommune price target raised to $65 from $35 at H.C. Wainwright

Evommune's Stock Surges On Strong Results For New Eczema Drug

Benzinga_recent_news

BUZZ-Evommune soars after eczema therapy shows promise in mid-stage trial

Evommune jumps 67% to $28.13 after atopic dermatitis data

Evommune reports EVO301 trial met primary endpoint

Evommune meldet positive Phase-2a-Studienergebnisse für EVO301 bei atopischer Dermatitis

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EVMN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"EVMN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","market":"US","secType":"STK","nameCN":"Evommune","latestPrice":28.31,"timestamp":1771621200000,"preClose":28.73,"halted":0,"volume":389573,"hourTrading":{"tag":"盘后","latestPrice":28.32,"preClose":28.31,"latestTime":"19:58 EST","volume":798,"amount":22529.6482,"timestamp":1771635511539,"change":0.01,"changeRate":0.000353,"amplitude":0.006711},"delay":0,"changeRate":-0.014618865297598389,"floatShares":9400000,"shares":31524093,"eps":-1.993,"marketStatus":"Market Closed","change":-0.42,"latestTime":"02-20 16:00:00 EST","open":28.6,"high":29.64,"low":26.5,"amount":11008440.85783,"amplitude":0.109293,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.993,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"listingDate":1762405200000,"exchange":"NYSE","adjPreClose":28.73,"preHourTrading":{"tag":"盘前","latestPrice":29.01,"preClose":28.73,"latestTime":"09:25 EST","volume":1039,"amount":30382.168899,"timestamp":1771597500088,"change":0.28,"changeRate":0.009746,"amplitude":0.03968},"postHourTrading":{"tag":"盘后","latestPrice":28.32,"preClose":28.31,"latestTime":"19:58 EST","volume":798,"amount":22529.6482,"timestamp":1771635511539,"change":0.01,"changeRate":0.000353,"amplitude":0.006711},"volumeRatio":0.5721606468364013},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","floatShares":9400000,"roa":"--","roe":"--","lyrEps":-45.287292,"volumeRatio":0.5721606468364013,"shares":31524093,"dividePrice":0,"high":29.64,"amplitude":0.109293,"preClose":28.73,"low":26.5,"week52Low":13.885,"pbRate":"-4.87","psRate":"68.65","week52High":33.2,"institutionHeld":0,"latestPrice":28.31,"eps":-1.993,"divideRate":0,"volume":389573,"delay":0,"ttmEps":-1.993,"open":28.6,"prevYearClose":17.12,"prevWeekClose":31.57,"prevMonthClose":18.1,"prevQuarterClose":17.12,"fiveDayClose":27.88,"twentyDayClose":18.89,"sixtyDayClose":18.71},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVMN\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVMN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVMN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1769144400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EVMN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EVMN","date":"2026-02-20","current":-14.204717,"percent":0.054054,"low":-16.229076,"twenty":-10.094711,"median":-9.253195,"eighty":-8.56425,"high":-7.430686,"avg":-9.72712,"sd":1.963524,"marketCap":905687191},"quantilePoints":[{"date":"2025-11-07","current":-9.395174,"twenty":-7.823584,"median":-7.430686,"eighty":-7.430686,"marketCap":608469038},{"date":"2025-11-14","current":-8.461694,"twenty":-9.04686,"median":-8.505813,"eighty":-7.430686,"marketCap":548013143},{"date":"2025-11-21","current":-8.689259,"twenty":-9.04686,"median":-8.689259,"eighty":-7.430686,"marketCap":562751147},{"date":"2025-11-28","current":-9.618094,"twenty":-9.051504,"median":-8.707835,"eighty":-8.049291,"marketCap":622906267},{"date":"2025-12-05","current":-10.184684,"twenty":-9.618094,"median":-8.986487,"eighty":-8.483986,"marketCap":659600890},{"date":"2025-12-12","current":-9.657505,"twenty":-9.633858,"median":-9.000419,"eighty":-8.483986,"marketCap":592227156},{"date":"2025-12-19","current":-7.716136,"twenty":-9.618094,"median":-8.986487,"eighty":-8.244704,"marketCap":473176635},{"date":"2025-12-26","current":-9.042428,"twenty":-9.528926,"median":-9.016673,"eighty":-8.355807,"marketCap":554508795},{"date":"2026-01-02","current":-8.800817,"twenty":-9.392482,"median":-9.003431,"eighty":-8.469125,"marketCap":539692472},{"date":"2026-01-09","current":-9.37143,"twenty":-9.380689,"median":-8.972554,"eighty":-8.293747,"marketCap":574684215},{"date":"2026-01-16","current":-10.075701,"twenty":-9.649623,"median":-9.019686,"eighty":-8.354639,"marketCap":617872222},{"date":"2026-01-23","current":-9.710714,"twenty":-9.690151,"median":-9.037572,"eighty":-8.461694,"marketCap":595490116},{"date":"2026-01-30","current":-11.129537,"twenty":-9.775997,"median":-9.042428,"eighty":-8.498847,"marketCap":682496613},{"date":"2026-02-06","current":-8.564346,"twenty":-9.775997,"median":-9.064213,"eighty":-8.549933,"marketCap":525191389},{"date":"2026-02-13","current":-14.332171,"twenty":-9.885497,"median":-9.065437,"eighty":-8.563866,"marketCap":878891712},{"date":"2026-02-20","current":-14.769127,"twenty":-10.094711,"median":-9.253195,"eighty":-8.56425,"marketCap":905687191}],"updateTime":1771796660104},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVMN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612428005","title":"Evommune price target raised to $54 from $36 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2612428005","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612428005?lang=en_us&edition=fundamental","pubTime":"2026-02-19 02:20","pubTimestamp":1771438832,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Judah Frommer raised the firm’s price target on Evommune (EVMN) to $54 from $36 and keeps an Overweight rating on the shares...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-price-target-raised-to-54-from-36-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-price-target-raised-to-54-from-36-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"gpt_icon":0},{"id":"2611415206","title":"BRIEF-Evommune Inc On Feb 12, Enters Securities Purchase Agreement With Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2611415206","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611415206?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:07","pubTimestamp":1770988053,"startTime":"0","endTime":"0","summary":"BRIEF-Evommune Inc On Feb 12, Enters Securities Purchase Agreement With Investors Feb 13  - Evommune Inc EVMN.N:EVOMMUNE INC - ON FEB 12, ENTERS SECURITIES PURCHASE AGREEMENT WITH INVESTORS - SEC FILINGEVOMMUNE INC - TO ISSUE AND SELL 4,494,279 SHARES OF COMMON STOCK - SEC FILINGEVOMMUNE INC - ESTIMATES GROSS PROCEEDS OF $125 MILLION - SEC FILINGEVOMMUNE INC - ENTERS REGISTRATION RIGHTS AGREEMENT WITH INVESTORS - SEC FILINGSource text: [ID:n0001193125-26-049888]Further company coverage: EVMN.N ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nFWN3Z91BQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"gpt_icon":0},{"id":"2611524401","title":"Evommune Inc - to Issue and Sell 4,494,279 Shares of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2611524401","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611524401?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:01","pubTimestamp":1770987683,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nFWN3Z91BQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"gpt_icon":0},{"id":"2611429152","title":"Evommune Inc - Estimates Gross Proceeds of $125 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2611429152","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611429152?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:01","pubTimestamp":1770987683,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nFWN3Z91BQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"gpt_icon":0},{"id":"2611414152","title":"Evommune Inc - on Feb 12, Enters Securities Purchase Agreement With Investors - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2611414152","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611414152?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:01","pubTimestamp":1770987683,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nFWN3Z91BQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"gpt_icon":0},{"id":"2611900362","title":"Evommune announces $125M private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2611900362","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611900362?lang=en_us&edition=fundamental","pubTime":"2026-02-13 09:35","pubTimestamp":1770946510,"startTime":"0","endTime":"0","summary":"Evommune (EVMN) announced that it has entered into a securities purchase agreement to sell 4,494,279 shares of its common stock to a select group o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-announces-125m-private-placement-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-announces-125m-private-placement-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","BK4139"],"gpt_icon":0},{"id":"2611907421","title":"Evommune Raises $125 Million in Private Placement of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2611907421","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611907421?lang=en_us&edition=fundamental","pubTime":"2026-02-13 09:30","pubTimestamp":1770946214,"startTime":"0","endTime":"0","summary":"Evommune Inc., a clinical-stage biotechnology company focused on therapies for chronic inflammatory diseases, has announced a private placement of 4,494,279 shares of its common stock to select new and existing mutual funds and healthcare institutional investors at a price of $27.88 per share. The transaction is expected to raise approximately $125 million in gross proceeds, before transaction-related expenses, and is anticipated to close on or about February 17, 2026, subject to customary closing conditions. The securities offered in this private placement have not been registered under the Securities Act of 1933 and may not be sold in the United States without registration or an applicable exemption. Evommune plans to use the net proceeds to advance its clinical development programs and for general corporate purposes. Morgan Stanley & Co. LLC, Leerink Partners LLC, Evercore ISI, Cantor Fitzgerald & Co., and William Blair & Company, L.L.C. acted as placement agents, with Oppenheimer &","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL4pMtxg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0006306889.USD","LU0106831901.USD","LU0314104364.USD","LU2357305700.SGD","BK4504","BK4581","LU1720051108.HKD","IE00BKVL7J92.USD","LU0158827948.USD","LU1732799900.SGD","LU1244550494.USD","LU2111349929.HKD","BK4534","LU2133065610.SGD","OPY","LU2089283258.USD","LU0320765646.SGD","BK4588","LU0882574139.USD","LU0912757837.SGD","LU1363072403.SGD","LU1548497426.USD","BK4207","LU2271345857.HKD","LU1989772923.USD","BK4516","LU0106261372.USD","LU1162221912.USD","LU0971096721.USD","LU0158827781.USD","MNSH","LU1244550577.SGD","LU0098860793.USD","IE00BZ1G4Q59.USD","LU0795875086.SGD","LU0528227936.USD","LU1244550221.USD","LU1720051017.SGD","LU1732800096.USD","EVR","LU1989772840.SGD","BK4127","LU1668664300.SGD","LU1074936037.SGD","EVMN","LU2023251221.USD","LU0225283273.USD","LU0795875169.SGD","LU2347655156.SGD","LU1791710582.SGD"],"gpt_icon":0},{"id":"2611907446","title":"Evommune Announces $125 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2611907446","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611907446?lang=en_us&edition=fundamental","pubTime":"2026-02-13 09:30","pubTimestamp":1770946200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nTUA1CPX0S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"gpt_icon":0},{"id":"2610950655","title":"Evommune (EVMN) Valuation Check After Positive Phase 2a EVO301 Results In Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2610950655","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610950655?lang=en_us&edition=fundamental","pubTime":"2026-02-12 00:31","pubTimestamp":1770827512,"startTime":"0","endTime":"0","summary":"Evommune (EVMN) is back in focus after reporting statistically significant positive top-line results from its Phase 2a EVO301 trial in moderate to severe atopic dermatitis, including clear separation from placebo and a favorable safety readout.\nSee our latest analysis for Evommune.\nThe positive EVO301 data has coincided with a sharp re-rating in the stock, with a 1-day share price return of 70.87% and a year-to-date share price return of 67.71% off a last close of $29.03. This indicates...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-evmn/evommune/news/evommune-evmn-valuation-check-after-positive-phase-2a-evo301","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-evmn/evommune/news/evommune-evmn-valuation-check-after-positive-phase-2a-evo301","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","EVMN"],"gpt_icon":0},{"id":"2610817669","title":"U.S. RESEARCH ROUNDUP-Coca-Cola, Rapid7, Walmart","url":"https://stock-news.laohu8.com/highlight/detail?id=2610817669","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610817669?lang=en_us&edition=fundamental","pubTime":"2026-02-11 16:12","pubTimestamp":1770797522,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Coca-Cola, Rapid7, WalmartFeb 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Coca-Cola, Rapid7","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL4N3Z70HQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW","CAH","NET","KO","LU0320765646.SGD","AEIS","PROK","WMB","RDN","DGX","KVYO","FTV","LU0738911758.USD","PRCH","LU1221951046.USD","COTY","ECL","LU1201861165.SGD","GILD","LU2108987350.USD","LU0154245756.USD","HNGE","MEDP","WCC","DD","FISV","BLKB","BL","LSCC","RPD","LYFT","LU1621767737.EUR","PANW","LU0238689110.USD","ICHR","NKTR","SAIA","EVMN","MAT","MAR","HAS","ACM","WMT","LU1670710588.SGD","UPST","MAS","ALL","DDOG","INCY"],"gpt_icon":0},{"id":"2610967355","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2610967355","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610967355?lang=en_us&edition=fundamental","pubTime":"2026-02-11 03:18","pubTimestamp":1770751137,"startTime":"0","endTime":"0","summary":"Evommune  said Tuesday its phase 2a proof-of-concept trial evaluating EVO301 as a treatment for atopic dermatitis achieved \"highly statistically significant\" results in adult patients with moderate-to-severe atopic dermatitis.Shares surged 73% as intraday trading volume soared to over 12.7 million from a daily average of roughly 228,000.European Wax Center  said Tuesday that it has agreed to be taken private by General Atlantic in an all-cash transaction valued at about $330 million.Shares of European Wax Center soared 43% as intraday trading volume catapulted to more than 10.2 million from a daily average of about 409,000.Ichor  posted a \"solid\" Q4 as it continues its recovery under its new chief executive officer, Phil Barros, targeting new opportunities in the semiconductor equipment market with a serviceable addressable market estimated at $9 billion, Oppenheimer said in a note emailed Tuesday.Shares jumped 32%, with intraday trading volume at over 4.3 million compared with a daily","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EWCZ","BK4192","BK4539","IE00B19Z4B17.USD","BK4139","IE00B7SZL793.SGD","IE0031619046.USD","IE00B66KJ199.SGD","BK4147","EVMN","ICHR"],"gpt_icon":0},{"id":"2610867868","title":"Evommune price target raised to $55 from $40 at Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2610867868","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610867868?lang=en_us&edition=fundamental","pubTime":"2026-02-11 02:36","pubTimestamp":1770748575,"startTime":"0","endTime":"0","summary":"Evercore ISI raised the firm’s price target on Evommune (EVMN) to $55 from $40 and keeps an Outperform rating on the shares. The firm says Evommune...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-price-target-raised-to-55-from-40-at-evercore-isi-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-price-target-raised-to-55-from-40-at-evercore-isi-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"gpt_icon":0},{"id":"2610678682","title":"Evommune: Robust IL-18 Phase 2a Atopic Dermatitis Data Underpins Buy Rating and Higher $55 Target with Additional Indication Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2610678682","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610678682?lang=en_us&edition=fundamental","pubTime":"2026-02-11 02:35","pubTimestamp":1770748533,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Gavin Clark-Gartner has maintained their bullish stance on EVMN stock, giving a Buy rating today. Gavin Clark-Gartner has give...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/evommune-robust-il-18-phase-2a-atopic-dermatitis-data-underpins-buy-rating-and-higher-55-target-with-additional-indication-upside-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/evommune-robust-il-18-phase-2a-atopic-dermatitis-data-underpins-buy-rating-and-higher-55-target-with-additional-indication-upside-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"gpt_icon":0},{"id":"2610620277","title":"Evommune Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2610620277","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610620277?lang=en_us&edition=fundamental","pubTime":"2026-02-11 02:14","pubTimestamp":1770747240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVMN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2026 13:14 ET (18:14 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"gpt_icon":0},{"id":"2610763620","title":"Evommune price target raised to $65 from $35 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2610763620","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610763620?lang=en_us&edition=fundamental","pubTime":"2026-02-11 01:55","pubTimestamp":1770746111,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Evommune (EVMN) to $65 from $35 and keeps a Buy rating on the shares afte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-price-target-raised-to-65-from-35-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-price-target-raised-to-65-from-35-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"gpt_icon":0},{"id":"2610620336","title":"Evommune's Stock Surges On Strong Results For New Eczema Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2610620336","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610620336?lang=en_us&edition=fundamental","pubTime":"2026-02-11 01:29","pubTimestamp":1770744540,"startTime":"0","endTime":"0","summary":"Evommune shares jumped after its mid-stage trial showed strong skin improvement and good safety for EVO301 in patients with moderate to severe eczema.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/10/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/10/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/02/50518722/evommunes-stock-surges-on-strong-results-for-new-eczema-drug","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/02/50518722/evommunes-stock-surges-on-strong-results-for-new-eczema-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4132","EASI","BK4139","BK4217","EVMN","AD","SMA"],"gpt_icon":0},{"id":"2610625561","title":"BUZZ-Evommune soars after eczema therapy shows promise in mid-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2610625561","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610625561?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:52","pubTimestamp":1770731521,"startTime":"0","endTime":"0","summary":"BUZZ-Evommune soars after eczema therapy shows promise in mid-stage trial ** Shares of drug developer Evommune EVMN.N jump 102.47% to $33.8 premarket ** Co says its experimental therapy, EVO301, met the main goal of a mid-stage trial, when tested in patients with moderate-to-severe atopic dermatitis  ** Atopic dermatitis, or eczema, is a chronic skin condition causing dry, itchy, inflamed skin due to a faulty skin barrier and overactive immune response** In a 70-patient trial, 23% of patients on EVO301 had clear or almost clear skin with a meaningful improvement, compared with patients on placebo** EVO301 is an injectable protein drug designed to block IL18, an inflammatory signal that is overactive in conditions like atopic dermatitis** Patients on co's therapy showed statistically significant reduction in their EASI scores - a standard measure of eczema severity - compared with people who received placebo by week 4, 8 and 12 of the study** EVMN says it is also evaluating potential ad","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nL4N3Z61JL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"gpt_icon":0},{"id":"2610056623","title":"Evommune jumps 67% to $28.13 after atopic dermatitis data","url":"https://stock-news.laohu8.com/highlight/detail?id=2610056623","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610056623?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:37","pubTimestamp":1770730656,"startTime":"0","endTime":"0","summary":"08:27 EST Evommune (EVMN) jumps 67% to $28.13 after atopic dermatitis data Published first on TheFly – the ultimate source for real-time, market-mo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-jumps-67-to-28-13-after-atopic-dermatitis-data-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-jumps-67-to-28-13-after-atopic-dermatitis-data-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","BK4139"],"gpt_icon":0},{"id":"2610640027","title":"Evommune reports EVO301 trial met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2610640027","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610640027?lang=en_us&edition=fundamental","pubTime":"2026-02-10 20:40","pubTimestamp":1770727258,"startTime":"0","endTime":"0","summary":"Evommune (EVMN) announced top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-reports-evo301-trial-met-primary-endpoint-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-reports-evo301-trial-met-primary-endpoint-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","BK4139"],"gpt_icon":0},{"id":"2610478647","title":"Evommune meldet positive Phase-2a-Studienergebnisse für EVO301 bei atopischer Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2610478647","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610478647?lang=en_us&edition=fundamental","pubTime":"2026-02-10 20:30","pubTimestamp":1770726656,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via Business Wire  on February 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDLhgP1k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":57,"code":"91000000","status":"200"}]}}